Reimbursed with a limitationOriginator productATC N07XX05

Firdapse

Firdapse is an originator product from DRAC AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 1'567.25 to CHF 1'567.25 depending on the pack; the patient co-payment is 10 per cent plus the deductible.

Core data

Authorisation holder
DRAC AG
ATC code
N07XX05
IT group
01.14 Myasthenia gravis
Active substances
Amifampridinum
Preparation type
Originator product
On the SL since
01/09/2025
Last price change
01/09/2025
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Firdapse Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Tabl 10 mg100 StkCHF 1'425.98CHF 1'567.2501/09/2025B7680618530019

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingValid from 01/09/2025

Die Behandlung mit FIRDAPSE bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.
Symptomatische Behandlung des Lambert-Eaton-Myasthenie Syndroms (LEMS) bei Erwachsenen.
FIRAPSE darf nur in Spital-basierten, spezialisierten neuromuskulären Zentren des Netzwerks Myosuisse https://myosuisse.org/ueber-uns/nationale-referenzzentren/ von einem Facharzt der Neurologie verschrieben werden.
In den sieben Zentren müssen alle LEMS-Patienten erfasst werden, welche mit FIRDAPSE therapiert werden. Die folgenden Angaben sind zu dokumentieren:
- Anzahl behandelter Patienten pro Kalenderjahr
- Therapiestart, Therapieende / pro Patient
- Bei Therapieabbruch: Begründung, weshalb die Therapie abgebrochen wurde
Der Therapieerfolg mit FIRDAPSE muss 12 Wochen nach Beginn der Behandlung überprüft werden.
Die Therapie mit FIRDAPSE muss abgesetzt werden, wenn keine Wirkung feststellbar.

FAQ

Is Firdapse covered by Swiss health insurance?

Yes, but only under conditions. Firdapse is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Firdapse cost in Switzerland?

The public price is the maximum price set by the FOPH and for Firdapse ranges from CHF 1'567.25 to CHF 1'567.25 per pack. The ex-factory price ranges from CHF 1'425.98 to CHF 1'425.98. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com